Text Size:AAA

IFNA14 Protein, Antibody, ELISA Kit, cDNA Clone

IFNA14 Related Areas

IFNA14 Related Pathways

IFNA14 Related Product

IFNA14 Summary & Protein Information

IFNA14 Background

Catalytic activity: Cholest-5-ene-3-beta,25-diol + NADPH + O(2) = cholest-5-ene-3-beta,7-alpha,25-triol + NADP(+) + H(2)O.
Cholest-5-ene-3-beta,27-diol + NADPH + O(2) = cholest-5-ene-3-beta,7-alpha,27-triol + NADP(+) + H(2)O.
Cofactor: Heme group (By similarity).
Subcellular location: Secreted.
Tissue specificity: Brain, testis, ovary, prostate, liver, colon, kidney, and small intestine.
Involvement in disease: Spastic paraplegia 5A, autosomal recessive (SPG5A) [MIM:270800]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Note=The disease is caused by mutations affecting the gene represented in this entry.
Congenital bile acid synthesis defect 3 (CBAS3) [MIM:613812]: A disorder resulting in severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable. Note=The disease is caused by mutations affecting the gene represented in this entry.
Sequence similarity: Belongs to the alpha/beta interferon family.C
General information above from UniProt

IFNA14 Alternative Name

LEIF2H,IFNA14,IFN-alphaH,MGC125756,MGC125757, [human]
Ifna14,MGC155959,OTTMUSG00000007662,RP23-67C1.2, [mouse]

IFNA14 Related Studies

  • Lau JY, et al. (1993) Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 342(8881): 1208-9.
  • Kessler DS, et al. (1990) Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 4(10): 1753-65.
  • Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 91(4): 1198-205.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"